These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 6339196)

  • 61. Specific binding of the calcium antagonist [3H]verapamil to membrane fractions from plants.
    Andrejauskas E; Hertel R; Marmé D
    J Biol Chem; 1985 May; 260(9):5411-4. PubMed ID: 3157687
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Effects of verapamil, diltiazem, and nifedipine on plasma levels and renal excretion of digitoxin.
    Kuhlmann J
    Clin Pharmacol Ther; 1985 Dec; 38(6):667-73. PubMed ID: 3905167
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Dissociation of cardiodepression from cardioprotection with calcium antagonists: diltiazem protects ischemic rat myocardium with a lower functional cost as compared with verapamil or nifedipine.
    Grover GJ; Sleph PG
    J Cardiovasc Pharmacol; 1989 Aug; 14(2):331-40. PubMed ID: 2476610
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Effects of hemodynamic changes on the elimination kinetics of verapamil and nifedipine.
    Hamann SR; Blouin RA; Chang SL; Kaltenborn KE; Tan TG; McAllister RG
    J Pharmacol Exp Ther; 1984 Nov; 231(2):301-5. PubMed ID: 6491984
    [TBL] [Abstract][Full Text] [Related]  

  • 65. L-type calcium channel antagonism - Translation from in vitro to in vivo.
    Fermini B; Ramirez DS; Sun S; Bassyouni A; Hemkens M; Wisialowski T; Jenkinson S
    J Pharmacol Toxicol Methods; 2017; 84():86-92. PubMed ID: 27856310
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Effects of nifedipine, verapamil and diltiazem on serum biochemical parameters and aortic composition of atherosclerotic chickens.
    García-Pérez B; Ayala I; Castells MT; Doménech G; Sánchez-Polo MT; García-Partida P; Valdés M
    Biomed Pharmacother; 2005; 59(1-2):1-7. PubMed ID: 15740928
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Verapamil disposition kinetics in chronic atrial fibrillation.
    Kates RE; Keefe DL; Schwartz J; Harapat S; Kirsten EB; Harrison DC
    Clin Pharmacol Ther; 1981 Jul; 30(1):44-51. PubMed ID: 7237897
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Pharmacokinetics and bioavailability of diltiazem (CRD-401) in dog.
    Kohno K; Takeuchi Y; Etoh A; Noda K
    Arzneimittelforschung; 1977 Jul; 27(7):1424-8. PubMed ID: 578467
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Inhibitor effects of diltiazem, nicardipine, nifedipine and verapamil on the norepinephrine-induced contractions of the canine saphenous vein in calcium-free medium.
    Saïag B; Milon D; Bentue-Ferrer D; Allain H; Rault B; Van den Driessche J
    Res Commun Chem Pathol Pharmacol; 1994 Mar; 83(3):255-69. PubMed ID: 8008975
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Clinical pharmacokinetics of amlodipine.
    Meredith PA; Elliott HL
    Clin Pharmacokinet; 1992 Jan; 22(1):22-31. PubMed ID: 1532771
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Absence of a dose-response of cyclosporine levels to clinically used doses of diltiazem and verapamil.
    Jacob LP; Malhotra D; Chan L; Shapiro JI
    Am J Kidney Dis; 1999 Feb; 33(2):301-3. PubMed ID: 10023642
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Effects of calcium channel blockers on the pharmacokinetics of propranolol stereoisomers.
    Hunt BA; Bottorff MB; Herring VL; Self TH; Lalonde RL
    Clin Pharmacol Ther; 1990 May; 47(5):584-91. PubMed ID: 2344707
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The metabolism and pharmacokinetics of nicardipine hydrochloride in man.
    Graham DJ; Dow RJ; Hall DJ; Alexander OF; Mroszczak EJ; Freedman D
    Br J Clin Pharmacol; 1985; 20 Suppl 1(Suppl 1):23S-28S. PubMed ID: 4027149
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Calcium channel blockers: spectrum of side effects and drug interactions.
    Hedner T
    Acta Pharmacol Toxicol (Copenh); 1986; 58 Suppl 2():119-30. PubMed ID: 2872768
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Simultaneous determination of the intravenous and oral pharmacokinetic parameters of D,L-verapamil using stable isotope-labelled verapamil.
    Eichelbaum M; Somogyi A; von Unruh GE; Dengler HJ
    Eur J Clin Pharmacol; 1981 Jan; 19(2):133-7. PubMed ID: 7202473
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Pharmacokinetics of diltiazem after intravenous and oral administration.
    Hermann P; Rodger SD; Remones G; Thenot JP; London DR; Morselli PL
    Eur J Clin Pharmacol; 1983; 24(3):349-52. PubMed ID: 6861848
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Cutaneous reactions due to diltiazem and cross reactivity with other calcium channel blockers.
    Gonzalo Garijo MA; Pérez Calderón R; de Argila Fernández-Durán D; Rangel Mayoral JF
    Allergol Immunopathol (Madr); 2005; 33(4):238-40. PubMed ID: 16045866
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Effects of nifedipine and diltiazem on pharmacokinetics of cefpodoxime following its oral administration.
    Deslandes A; Camus F; Lacroix C; Carbon C; Farinotti R
    Antimicrob Agents Chemother; 1996 Dec; 40(12):2879-81. PubMed ID: 9124858
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Pharmacokinetics of the enantiomers of verapamil after intravenous and oral administration of racemic verapamil in a rat model.
    Bhatti MM; Foster RT
    Biopharm Drug Dispos; 1997 Jul; 18(5):387-96. PubMed ID: 9210977
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Clinical pharmacology of slow channel blocking agents.
    McAllister RG
    Prog Cardiovasc Dis; 1982; 25(2):83-102. PubMed ID: 7051139
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.